Weekly issue 2026-W40 ·
CFTR correctors suppress Ca²⁺-cAMP signaling and cyst growth in primary cultures of ARPKD cholangiocytes
Plain language
Recessive PKD (ARPKD) affects both the kidneys and the liver’s bile ducts, and there is no targeted treatment for the liver part. In bile-duct cells from mice with ARPKD, two cystic fibrosis medicines that help the CFTR protein work (CFTR correctors) calmed overactive cell signals and reduced cyst growth. Because these medicines are already approved for cystic fibrosis, this is a lead worth studying, but it has only been tested on cells in the lab.
Clinical note
Primary cholangiocytes from Pkhd1del3-4/del3-4 mice: reduced CFTR, PC1 and PC2; raised resting Ca²⁺, larger thapsigargin-releasable ER store, STIM1 up, IP₃R down, markedly raised cAMP with AC6→AC3 isoform switch. VX-809 and VX-445 increased CFTR, partly restored PC1/PC2, attenuated Ca²⁺/cAMP signalling, proliferation and cyst growth, and normalised CFTR membrane distribution; CFTRinh-172 did not reproduce these effects. In vitro only — supports in vivo testing of approved correctors for ARPKD hepatobiliary disease.
Question for your next visit
For my child with ARPKD, how is the liver being monitored, and are there research studies on liver treatments we should know about?